New device aims to sharpen liver tumor ablation
NCT ID NCT05582018
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This pilot study tested a device called BioTraceIO 360, designed to help doctors plan and monitor procedures that destroy liver tumors using heat. The study planned to enroll 30 people with liver cancer, but only 4 participated before it was stopped early. Researchers looked at whether the device's suggestions matched the doctor's own plans and if any device-related side effects occurred.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BioTraceIO 360 device
What this could lead to
If successful, this device could help doctors more accurately plan and monitor liver tumor ablation procedures, potentially improving outcomes.
What could go wrong
This was a very small pilot study (only 4 participants) that was terminated early. The device may not work as intended or may not be better than standard planning methods.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Einstein Medical Center
Philadelphia, Pennsylvania, 19141, United States